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Introduction
A cerebrospinal fluid (CSF) leak presenting with rhinorrhoea
or otorrhoea occurs when there is a fistula between the dura
and the skull base. This can be due to traumatic or non-
traumatic causes. Ascending bacterial infection causing
meningitis or intracranial sepsis is the major concern.1,2
Persistent rhinorrhoea or otorrhoea may indicate an unhealed
fistula, which requires invasive procedures for localization
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BACKGROUND: This report describes the sensitivity and specificity of glucose detection using Glucostix test
strips and computed tomography (CT) of the skull base for confirming cerebrospinal fluid (CSF) fistulae in
patients with persistent rhinorrhoea or otorrhoea, and comparing them with the beta-2 transferrin assay as the
gold standard for CSF detection.
METHODS: Fluid samples from the nose were collected from 18 patients with suspected CSF fistulae. The
samples were assayed for beta-2 transferrin using the Western blotting and immunostaining technique. CT (5 mm
axial slice) of the skull base was performed for evidence of skull base fracture. The glucose levels and Glucostix
results were compared.
RESULTS: Out of the 18 samples, 15 were positive for beta-2 transferrin and the leaks were validated surgically
in 10 patients. Five leaks healed spontaneously with conservative management. Glucostix tests produced three
false positive results from blood and nasal mucus contaminated fluid. Glucostix failed to detect another three CSF
leaks resulting from false negative tests because of low CSF glucose levels. The Glucostix glucose test was non-
specific and insensitive compared with the beta-2 transferrin assay. CT failed to detect three out of the 15 beta-
2 transferrin-positive leaks but there were no false positive results. CT produced six negative results, of which three
were false negatives.
CONCLUSIONS: Glucose detection using Glucostix test strips is not recommended as a confirmatory test due
to its lack of specificity and sensitivity. In the presence of a skull base fracture on CT and a clinical CSF leak, there
is no need for a further confirmatory test. In cases where a confirmatory test is needed, the beta-2 transferrin assay
is the test of choice because of its high sensitivity and specificity.  [Asian J Surg 2004;27(1):39–42]
and repair.3–7 However, coincidental nasal or ear discharge or
bleeding may confuse the diagnosis.
Testing for the presence of glucose in sample fluid from
the nose and ear suspected to contain CSF using Glucostix test
strips (Roche, Indianapolis, IN, USA) has been a traditional
bedside test for the detection of CSF leaks. Nonetheless, there
is dispute over its sensitivity and specificity, and it is unclear
whether it is a reliable clinical tool.
CSF can leak through a bony breach at the skull base,
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which is often visible with computed tomography (CT). The
development of fine-slice CT has increased the degree of
confidence in diagnosing CSF leaks.
Beta-2 transferrin is a carbohydrate-free (desialated)
isoform of transferrin, which is almost exclusively found in the
CSF.8–15 Beta-2 transferrin is not present in blood, nasal mucus,
tears or mucosal discharge. This protein was first described by
Irjala et al in 1979.10 Intense research over the last decade has
validated its characteristics and value in clinical use as a specific
CSF marker.9–13,16–19
Beta-2 transferrin assay of the sample fluid is employed to
detect the presence of CSF and to confirm an unhealed fistula.
The sensitivity and specificity of Glucostix test strips and CT
(5 mm axial slice) were assessed, and the results compared with
those of the beta-2 transferrin assay, which was used as the
gold standard.
Patients and methods
Fluid samples from the nose and ear were collected from
patients presenting with rhinorrhoea and otorrhoea who were
suspected of having CSF leaks. The fluid samples were tested
for beta-2 transferrin by centrifugation, polyacrylamide gel
electrophoresis, Western blotting, and immunostaining. At
least three or four dilutions of each sample and a positive CSF
control were assayed in parallel for each patient (Figure).
Glucose levels in nasal and ear discharge were measured in
the biochemistry department, and Glucostix test strips (Roche)
were used to test the glucose levels for comparison. CT (5 mm
axial slice) of the skull base was performed in all patients to
look for features of skull base fractures (fracture lines in the
anterior and middle cranial fossa, fluid/blood levels over the
paranasal sinus or mastoid region, or pneumocranium).
Results
Eighteen patients with suspected CSF leaks were studied (Table
1). Half of the leaks were caused by trauma, while non-traumatic
causes accounted for the remainder. Of the 18 patients sampled,
15 were positive for beta-2 transferrin. In 10 patients, CSF
fistulae were surgically validated. The leaks of five patients
healed spontaneously with conservative management. Three
patients were found not to have a leak. All patients were
clinically well prior to the event.
Only samples from 12 of the 15 patients identified by
Glucostix as having CSF leaks were actually positive for glucose;
Glucostix resulted in three false positive results due to blood
in the nasal discharge. Glucostix missed three CSF leaks because
the CSF glucose level was lower than the detection limit of the
test. The CSF glucose levels in these three samples were 2.2 to
2.8 mmol/L.
CT failed to detect three of the 15 beta-2 transferrin-
positive CSF leaks (sensitivity = 0.8), but produced no false
positive result (positive predicting value = 1). CT produced a
total of six negative results, of which three were false negative
results (i.e. CSF was leaking, specificity = 1, negative predictive
value = 0.5).
By accepting the scientific basis of beta-2 transferrin as
being CSF-specific, and the uncomplicated clinical outcomes
of the 18 patients studied, beta-2 transferrin was our standard
for comparison with CT (Table 2) and Glucostix (Table 3). CT
had a sensitivity of 80%, with 100% positive predictive value for
the detection of CSF leaks. Glucostix test strips were non-
specific (specificity = 0), and the sensitivity was only 80% when
measuring glucose in the nasal and ear discharge of patients
suspected of having CSF leaks.
Discussion
About 90% of CSF leaks close spontaneously within 7 to 10
days. The remaining 10% of fistulae persist for more than 1
month. These fistulae carry a high risk for ascending meningitis,
the outcome of which may be devastating.6 Prompt diagnosis
and early management of CSF leaks minimize the risks of
infection. Intermittent leaks into contaminated body fluids
Figure. Column 1 shows the negative control (patient’s serum),
which has a beta-1 transferrin band only. Columns 2 and 3 show the
CSF positive controls at different dilutions, which have beta-2
transferrin as well as beta-1 transferrin bands. Columns 4 and 5
show the sample fluid (blood-stained nasal discharge) at different
dilutions, which have clear beta-2 transferrin bands (from the CSF)
and thick bands of contaminants (from blood), confirming the CSF
leak.
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such as blood, nasal discharge, mucus and tears often make
confirmatory diagnoses with traditional methods such as
Glucostix difficult.
Detection of glucose in the sample fluid using Glucostix
test strips has been the traditional method for detection of the
presence of CSF in nasal and ear discharge. Interpretation of
the results is confounded by various factors such as
contamination from glucose-containing fluid (tears, nasal
mucus, blood in nasal mucus) or relatively low CSF glucose
levels (meningitis). Most commercial glucose test strips employ
the glucose-oxidase enzyme, which causes colour changes to
the chromogen, visualized at glucose levels of 4 mmol/L or
more. This is at the high-normal reference range for CSF
glucose. Glucostix may fail to detect glucose at the CSF low-
normal range (2.8–3.5 mmol/L). The value of the Glucostix
test should have been discounted after Steedman and Gordon’s
simple and well-designed study published in 1987.20 The study
discovered that 26% of nasal discharge and tear samples from
normal subjects contained glucose levels within the normal
range of CSF (2.8–4.2 mmol/L).
Our data suggest that CT may be a useful tool for helping
to diagnose and localize clinical CSF leaks. Clinical rhinorrhoea
or otorrhoea and a corresponding skull base fracture that has
already been located on CT are indicative of a CSF leak; further
confirmatory testing is unnecessary. However, CT does miss
some fractures, yielding a negative predictive value of 0.5.
Conventional confirmation tests such as cisternography
and surgical exploration are invasive.3–6 Non-specific tests
subject patients to unnecessary invasive and risky procedures.
Non-sensitive tests delay treatment. The discovery of beta-2
transferrin has solved many of the above problems and can be
used to quickly diagnose a CSF fistula.
Beta-2 transferrin is almost exclusively found in CSF. The
assay is essentially unaffected by contamination because
centrifugation prior to testing removes cellular and large
particle contaminants. Furthermore, immunostaining is
protein-specific. As little as 2 µL of sample fluid is required for
the assay, and extraction of the fluid from an absorptive plug
is feasible.
Beta-2 transferrin was reported to have a sensitivity of near
100% and a specificity of about 95% in a large retrospective
study.18 This CSF-specific and protein-specific assay has
essentially replaced surgical validation as the test standard.
We do not recommend Glucostix for detection of glucose
as a confirmatory test for CSF leaks due to its lack of specificity
and sensitivity. In the presence of a radiologically-related (CT)
skull base fracture and clinical CSF leak, there is no need for a
further confirmatory test. In cases where a confirmatory test is
required, beta-2 transferrin assay is the test of choice because
of its high sensitivity and specificity. It should be used prior to
Table 1. Summary of test results in 18 patients
Patient Beta-2 Glucostix Computed
transferrin tomography
1 + + –
2 + + +
3 + + +
4 + + +
5 + + +
6 – + –
7 – + –
8 + + +
9 – + –
10 + + –
11 + + +
12 + + +
13 + + +
14 + + +
15 + + +
16 + – +
17 + – +
18 + – –
Table 2. Comparison of computed tomography (CT) results with
beta-2 transferrin assay results
Beta-2 transferrin
Positive Negative
CT positive 12 0 PPV = 1
CT negative 3 3 NPV = 0.5
S = 0.8 SP = 1
PPV = positive predictive value; NPV = negative predictive value;
S = sensitivity; SP = specificity.
Table 3. Comparison of Glucostix results with beta-2 transferrin
assay results
Beta-2 transferrin
Positive Negative
Glucostix positive 12 3 PPV = 0.8
Glucostix negative 3 0 NPV = 0
S = 0.8 SP = 0
PPV = positive predictive value; NPV = negative predictive value;
S = sensitivity; SP = specificity.
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invasive procedures for the localization and repair of CSF
fistulae.
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